{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:11:17Z","timestamp":1748491877015,"version":"3.41.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.rce.2015.05.002","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T21:02:03Z","timestamp":1434661323000},"page":"385-390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dabigatr\u00e1n: experiencia en la pr\u00e1ctica cl\u00ednica habitual"],"prefix":"10.1016","volume":"215","author":[{"given":"J.","family":"\u00c1lvarez-Otero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"de la Fuente-Aguado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Arias-Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gonz\u00e1lez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Puerta-Louro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ara\u00fajo-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rce.2015.05.002_bib0130","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.clinthera.2014.07.016","article-title":"Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in 4 European countries","volume":"36","author":"Cott\u00e9","year":"2014","journal-title":"Clin Ther."},{"key":"10.1016\/j.rce.2015.05.002_bib0135","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","article-title":"Dabigatran etexilate: A new oral thrombin inhibitor","volume":"123","author":"Hankey","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.rce.2015.05.002_bib0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rce.2015.05.002_bib0145","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2015.05.002_bib0150","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in real-world patients with atrial fibrillation","volume":"61","author":"Larsen","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rce.2015.05.002_bib0155","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.rce.2015.05.002_bib0160","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.amjcard.2013.08.027","article-title":"Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors","volume":"112","author":"Artang","year":"2013","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.rce.2015.05.002_bib0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2796.2011.02354.x","article-title":"Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction","volume":"270","author":"Christersson","year":"2011","journal-title":"J Intern Med."},{"key":"10.1016\/j.rce.2015.05.002_bib0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.amjmed.2013.12.005","article-title":"Myocardial ischemic events in \u2018real world\u2019 patients with atrial fibrillation treated with dabigatran or warfarin","volume":"127","author":"Larsen","year":"2014","journal-title":"Am J Med."},{"key":"10.1016\/j.rce.2015.05.002_bib0175","unstructured":"U.S. Food and Drug Administration [consultado 15 Sep 2014]. Disponible en: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm396470.htm"},{"key":"10.1016\/j.rce.2015.05.002_bib0180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase risk for gastrointestinal bleeding: A systematic review and meta-analysis","volume":"145","author":"Holster","year":"2013","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rce.2015.05.002_bib0185","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.amjcard.2013.11.049","article-title":"Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran","volume":"113","author":"Bloom","year":"2014","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.rce.2015.05.002_bib0190","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The use of dabigatran in elderly patients","volume":"171","author":"Legrand","year":"2011","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.rce.2015.05.002_bib0195","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4140\/TCP.n.2014.169","article-title":"Dabigatran for stroke prevention in nonvalvularauricular auricular fibrillation: Focus in the geriatric population","volume":"29","author":"Brunetti","year":"2014","journal-title":"Consult Pharm."},{"key":"10.1016\/j.rce.2015.05.002_bib0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/ph5020155","article-title":"Concerns regarding the use of dabigatran for stroke prevention inauricular auricular fibrilation","volume":"5","author":"Stollberger","year":"2012","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.rce.2015.05.002_bib0205","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1253\/circj.CJ-13-0465","article-title":"Stroke prevention with oral anticoagulation therapy in patients withauricular auricular fibrillation--focus on the elderly","volume":"77","author":"Lip","year":"2013","journal-title":"Circ J."},{"key":"10.1016\/j.rce.2015.05.002_bib0210","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1160\/TH12-08-0542","article-title":"The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrialauricular fibrillation","volume":"109","author":"Azoulay","year":"2013","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.rce.2015.05.002_bib0215","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/jcph.335","article-title":"An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis","volume":"54","author":"Wilson","year":"2014","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.rce.2015.05.002_bib0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4212\/cjhp.v67i1.1322","article-title":"Management of severe dabigatran-related hemorrhage: Case report, considerations for management, and recommendations","volume":"67","author":"Plener","year":"2014","journal-title":"Can J Hosp Pharm."},{"key":"10.1016\/j.rce.2015.05.002_bib0225","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin","volume":"128","author":"Majeed","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.rce.2015.05.002_bib0230","first-page":"A17765","article-title":"A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteer","volume":"128","author":"Glund","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.rce.2015.05.002_bib0235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1756285614528064","article-title":"Dabigatran etexilate for secondary stroke prevention: The first year experience from a multicenter short-term registry","volume":"7","author":"Tsivgoulis","year":"2014","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1016\/j.rce.2015.05.002_bib0240","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.recesp.2012.06.006","article-title":"An\u00e1lisis coste-efectividad de dabigatr\u00e1n para la prevenci\u00f3n de ictus y embolia sist\u00e9mica en fibrilaci\u00f3n auricular no valvular en Espa\u00f1a","volume":"65","author":"Gonz\u00e1lez-Juanatey","year":"2012","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rce.2015.05.002_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention inauricular auricular fibrillation","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rce.2015.05.002_bib0250","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1161\/STROKEAHA.111.641027","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack","volume":"43","author":"Kamel","year":"2012","journal-title":"Stroke."}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256515001757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256515001757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:49:20Z","timestamp":1748458160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014256515001757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0014256515001757"],"URL":"https:\/\/doi.org\/10.1016\/j.rce.2015.05.002","relation":{},"ISSN":["0014-2565"],"issn-type":[{"type":"print","value":"0014-2565"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dabigatr\u00e1n: experiencia en la pr\u00e1ctica cl\u00ednica habitual","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2015.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.","name":"copyright","label":"Copyright"}]}}